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Previous studies have revealed that transforming growth factor--activated protein kinase 1 (TAB1) inter-
acts with p38 and induces p38 autophosphorylation. Here, we examine the sequence requirements in TAB1
and p38 that drive their interaction. Deletion and point mutations in TAB1 reveal that a proline residue in
the C terminus of TAB1 (Pro412) is necessary for its interaction with p38. Furthermore, a cryptic D-domain-
like docking site was identified adjacent to the N terminus of Pro412, putting Pro412 in the B3 position of
the docking site. Through mutational analysis, we found that the previously identified hydrophobic docking
groove in p38 is involved in this interaction, whereas the CD domain and ED domain are not. Furthermore,
chimeric analysis with p38 (which does not bind to TAB1) revealed a previously unidentified locus of p38
comprising Thr218 and Ile275 that is essential for specific binding of p38 to TAB1. Converting either of these
residues to the corresponding amino acid of p38 abolishes p38 interaction with TAB1. These p38 mutants
still can be fully activated by p38 upstream activating kinase mitogen-activated protein kinase kinase 6, but
their basal activity and activation in response to some extracellular stimuli are reduced. Adjacent to Thr218
and Ile275 is a site where large conformational changes occur in the presence of docking-site peptides derived
from p38 substrates and activators. This suggests that TAB1-induced autophosphorylation of p38 results
from conformational changes that are similar but unique to those seen in p38 interactions with its substrates
and activating kinases.
Intracellular signal transduction pathways regulate cellular
responses to physiological and nonphysiological stimuli. Spe-
cific protein-protein interactions determine the efficiency and
fidelity of these signaling pathways. The family of mitogen-
activated protein kinases (MAPKs) includes extracellular reg-
ulated protein kinase (ERK), c-Jun N-terminal kinase (JNK),
stress-activated protein kinase, and p38 (7, 8, 24, 41, 48).
MAPK activation results from phosphorylation in its activation
lip at a single tyrosine-threonine residue by specific MAPK
kinases (MKKs) (1). Inactivation of MAPK results from de-
phosphorylation of cognate residues by various tyrosine phos-
phatases and/or dual-specificity MAPK phosphatases (26, 47).
MAPKs catalyze the phosphorylation of their targets, which
include transcription factors and protein kinases (9, 15, 22, 25,
34, 37). Although a large number of molecules are involved in
the phosphorylation cascades of MAPKs, each MAPK cascade
is specifically regulated without cross talk inside cells. The
molecular basis for the fidelity of these reactions is partly
determined by the specificity of the interactions between ki-
nases and substrates. Scaffolding proteins that organize path-
ways in specific modules through simultaneous binding of sev-
eral components also play an important role in controlling the
specificity of MAPK cascades (49). Although the kinase cas-
cade is the primary activation mechanism of MAPKs, interac-
tion with transforming growth factor--activated protein ki-
nase 1 (TAK1)-binding protein 1 (TAB1) or phosphorylation
on Tyr323 by tyrosine kinase Zap70 (12, 36) can also promote
autoactivation of MAPK p38, suggesting that autoactivation
is a potential alternative mechanism of activation for other
MAPKs as well.
MAPKs are known to interact with their substrates and
processing enzymes (kinases and phosphatases) at sites outside
the active site of the enzyme (5, 11, 50). The best-studied
example of this is between D-domain peptides, which are
found on substrates and processing enzymes, and hydrophobic
docking sites found on MAPKs (2, 16, 21, 38, 45). D-domain
peptides have a consensus motif (Arg/Lys)2-(X)2-6-A-X-B
with a hydrophobic subregion that has been observed crystal-
lographically bound to a hydrophobic groove in the C-terminal
domain of the kinase (5). The site was later confirmed by
mutagenic analysis, and a similar interaction was observed
between JNK1 and JIP (20). Adjacent to the site is a region of
negatively charged residues (Asp313, Asp315, and Asp316 in
p38) called the CD domain (43). In the crystallographic struc-
ture of p38 in the presence of substrate- and activator-derived
D-domain peptides, allosteric conformational changes were
observed that affected the structure of the activation loop (5).
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This suggests that docking-site interactions, in addition to de-
termining the specificity of the kinase, also have a role in its
activation.
TAB1 was originally identified as an interacting protein of
TAK1 (39). We later found that it interacts with p38 but no
other p38 family member (12), and that TAB1b, a splice vari-
ant of TAB1 in which the 69 C-terminal residues are replaced
by a different 27-residue sequence, interacts only with p38
and not TAK1 (13). The interaction of TAB1 with p38 leads
to p38 autophosphorylation on the dual phosphorylation sites
in the activation lip both in vitro and in cells coexpressing
TAB1 and p38. TAB1-dependent p38 activation appears to
play a role in some physiological and pathological processes
such as injury during myocardial ischemia (42), maturation of
monocyte-derived dendritic cells (30), maintenance of periph-
eral T-cell anergy (32), and intracellular infection of parasite-
induced interleukin-12 production (27). On the other hand,
phosphorylation of TAB1 by p38 has been observed and may
play a role in negative feedback of TAK1 activation (6). Be-
cause of the unique nature of TAB1-p38 binding, we chose to
use a mutagenic approach to investigate the physical basis for
this interaction. We have mapped sequences in TAB1 required
for p38 binding, and we have determined that Pro412 is
especially important. With this in mind, a cryptic D-domain-
like docking site was identified in TAB1 adjacent to the N
terminus of Pro412, suggesting that TAB1 utilizes docking
interactions with features similar to those of p38 substrates
and activating enzymes. Important interaction sites in p38
were also identified, revealing that Ile116 and Gln120 of the
hydrophobic docking groove and two previously unidentified
residues, Thr218 and Ile275, are critical for TAB1 interactions.
On the other hand, mutations in the CD (43) and ED (44)
domains had no effect on p38-TAB1 interaction. Therefore,
the specific interaction between p38 and TAB1 involves both
common and unique structural determinants.
MATERIALS AND METHODS
Construction of expression vectors. The TAB1, Flag-p38, Flag-p38, Flag-
p38(CDmut), Flag-p38(EDmut), and TAB1/419-504 expression vectors were
described in previous publications (12, 31). The TAB1 deletion mutants were
generated by PCR. The p38 and p38 chimeras were created by PCR recom-
bination. The TAB1, p38, and p38 point mutations were generated with a
QuickChange Site-Directed Mutagenesis kit (Stratagene).
Transfection of cells. HEK293 cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, 2 mM glutamine,
and 100-g/ml penicillin and streptomycin. Cells on six-well plates were tran-
siently transfected with 1 g (total) of plasmid DNA using Lipofectamine 2000
(Invitrogen).
Western blot and immunoprecipitation analysis. Total-cell lysates were pre-
pared using a lysis buffer composed of 20 mM Tris-HCl (pH 7.5), 120 mM NaCl,
10% glycerol, 1 mM Na3VO4, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluo-
ride, and 1% Triton X-100. Equal loading of cell protein extracts in sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was ensured
using Bio-Rad’s protein assay solution (Bio-Rad, Hercules, CA) and by staining
the transferred nitrocellulose membranes with Ponceau’s solution (Sigma, St.
Louis, MO). Standard Western blot methods were then used (17). Rabbit poly-
clonal antibodies raised against bacterium-expressed recombinant His-TAB1
protein, anti-Flag M2 monoclonal antibody (Sigma, St. Louis, MO), and anti-
phospho p38 (New England Biolabs, Beverly, MA) were used in immunoblotting.
For coimmunoprecipitation, cell lysates prepared as described above were incu-
bated with anti-Flag M2 beads (Sigma) and gently shaken for 4 h at 4°C. The
beads were washed three times with the lysis buffer and one time with 50 mM
Tris (pH 6.8). Then, 50 l SDS sample buffer was added, and the samples were
heated for 5 min at 100°C. The supernatant was applied to SDS-PAGE gels and
was detected by immunoblotting.
CD spectroscopy. Circular dichroism (CD) spectra were recorded at room
temperature using an Aviv 202 Series Circular Dichroism spectrometer, model
62DS (Aviv Instruments, Lakewood, NJ). The CD spectra were obtained in 10
mM phosphate buffer (pH 7.4) using a cell with a 0.2-cm path length. p38 was
expressed as described previously in the BL21(DE3) strain as an N-terminal His6
fusion protein and was purified by Ni-nitrilotriacetic acid agarose (QIAGEN)
and Mono Q (Pharmacia) columns. The purified protein was dialyzed against an
incubation buffer (10 mM phosphate; pH 7.4). The peptides SKGKSKRKKDL
RISCNSK (MKK3) and SSAQSTSKTSVTLSLVMPSQ (TAB1) were custom
synthesized and purified by Invitrogen (San Diego, CA). A threefold molar
excess of the MKK3 or TAB1 peptides was added to p38 at a concentration of
20 g/ml in the incubation buffer overnight at 4°C. The samples were incubated
at room temperature for an additional hour and then had their CD spectra
measured. The MKK3, TAB1, and p38 peptides were measured as controls.
Reporter gene assay. Cells were grown on 35-mm-diameter multiwell plates
and transiently transfected with GAL4-responsive luciferase plasmid or the NF-
B-dependent luciferase reporter plasmid. A -galactosidase expression plasmid
(pCMV--gal,]; Clontech, Palo Alto, CA) was used to control for transfection
efficiency. The total amount of DNA for each transfection was kept constant by
using the empty vector pcDNA3. Cell extracts were prepared 24 h later, and
-galactosidase and luciferase activities were measured.
In vitro pull down assay. GST fusion protein of TAB1 expressed in Esche-
richia coli strain BL21 was bound to glutathione-Sepharose 4B beads (Amersham
Biosciences, Uppsala, Sweden) by incubating the beads with bacteria lysates and
subsequently washing them. The amount of bound protein was about 2 mg/ml, as
estimated by SDS-PAGE. A total of 40 l of the 50% slurry of beads was added
to 200 l of cell lysate generated from 5  105 cells, and they were incubated at
4°C for 3 h. The beads were washed three times with lysis buffer and then
subjected to Western blot analysis.
Protein kinase assays. In vitro kinase assays were carried out at 37°C for 30
min using immunoprecipitates as kinases, 5 g of kinase substrate, 250 M ATP,
and 10 Ci of [	-32P]ATP in 20 l of kinase reaction buffer as previously
described (18, 23). Reactions were terminated by the addition of Laemmli sam-
ple buffer. Reaction products were resolved by 12% SDS-PAGE, and the extent
of protein phosphorylation was visualized by autoradiography.
RESULTS
Proline 412 in TAB1 is required for TAB1 to bind to p38.
In previous studies, we determined that TAB1 residues be-
tween Ser373 and Val418 are required for interaction with
p38 (12). To further analyze which sequences in TAB1 are
required for binding to p38, we generated additional deletion
and point mutants in TAB1. We coexpressed wild-type TAB1
and TAB1 mutants with Flag-p38 and carried out coimmuno-
precipitation assays. Consistent with our previous report (12),
wild-type TAB1 and TAB1/419-504 coprecipitated with p38
(Fig. 1A). The progressive deletion of TAB1 C-terminal se-
quences showed that the sequence between 408 and 418 was
required (Fig. 1A). Further deletions showed that while TAB1/
414-504 interacts with p38, deletions of two more C-termi-
nal amino acids, Pro412 and Ser413, abolished TAB1’s inter-
action with p38 (Fig. 1B). The point mutant TAB1/S413A
had little effect on TAB1’s interaction with p38. In contrast,
the mutant TAB1/P412A could not be pulled down by Flag-
p38 (Fig. 1C). Figure 1D summarizes the length and mutation
sites of the TAB1 mutants used in Fig. 1A to C and their ability
to bind with p38. To determine whether TAB1/P412A ex-
pressed in cells is a functional protein, we measured its activity
toward activation of TAK1. It is known that coexpression of
TAB1 with TAK1 in cells leads to TAK1 activation, which in
turn activates the NF-B reporter (39). We expressed the
NF-B promoter-driven luciferase reporter together with or
without TAK1, TAB1, and TAB1/P412A in different combina-
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tions. As previously reported (39), coexpression of TAB1 with
TAK1 led to high expression of the NF-B reporter gene (Fig.
1E). TAB1/P412A appeared to function in a manner similar to
that of wild-type TAB1 in the activation of TAK1 because
similar induction of NF-B reporter gene expression was ob-
served when TAB1/P412A was coexpressed with TAK1 (Fig.
1E). Therefore, Pro412 is essential for TAB1’s interaction with
p38 but not TAK1.
A kinase interaction motif similar to the docking sites in
MKK3 and myocyte enhancer factor 2A (MEF2A) appears to
exist in TAB1. Because Pro412 is essential for TAB1-p38
interaction and the sequence C-terminal of Pro412 is not re-
quired for this interaction, we closely examined the sequence
N-terminal to Pro412 in TAB1. A D-domain like motif adja-
cent to the N terminus of Pro412 was found. Figure 2A shows
a sequence alignment of TAB1 with docking motifs in p38
substrates and activators. The motif in TAB1 varied from the
consensus motif found in p38 substrates and modifying en-
zymes in that it has only a single positively charged amino acid
(K-X4-A-X-B). To determine whether this D-domain plays a
role in TAB1-p38 interaction, we generated a few D-domain
mutations in TAB1. Deletion of the D-domain-like sequence
in TAB1 (TAB1/402-409) abolished TAB1-p38 interaction
(Fig. 2B), confirming that this D-domain like motif is a docking
site for p38. However, as its sequence already indicated, the
D-domain in TAB1 was atypical. Mutations of both A and B
(TAB1/L407A; L409A) or single B (TAB1/S408A/L409A) in
TAB1 only reduced TAB1’s affinity to p38 (Fig. 2B). Mutat-
ing K402 (TAB1/K402A) did not affect TAB1’s interaction
with p38 (Fig. 2B). Therefore, the D-domain in TAB1 has
both similarities and differences in comparison to previously
described D-domains.
Crystallographic structures of p38 bound to peptides from
MEF2A or MKK3 have revealed that A-X-B residues of the
docking site bind to p38 in a groove composed in part of
Ile116 and Gln120 (5). To determine whether these two resi-
dues are also required for p38 to interact with TAB1, we
performed coimmunoprecipitation assays, which revealed that
Ile116 and Gln120 mutations abolished the interaction be-
tween p38 and TAB1 (Fig. 2C). Thus, the hydrophobic dock-
ing groove apparently played a role in TAB1-p38 interaction.
However, it should be noted that p38 had a sequence iden-
tical to that of p38 in the docking groove (see Fig. S1 in the
supplemental material) but could be coimmunoprecipitated
with TAB1 (Fig. 2C). Therefore, another domain(s) in p38
must be required for the specific interaction between p38 and
TAB1.
CD and ED domains are not required for p38-TAB1 inter-
action. The CD domain in p38 (Asp313, Asp315, and
Asp316) was shown to be required for its interaction with its
FIG. 1. Pro412 of TAB1 is required for TAB1-p38 interaction. (A) TAB1 C-terminal truncated mutants TAB1/387-504, TAB1/395-504,
TAB1/408-504, and TAB1/419-504 were coexpressed with Flag-p38 in 293 cells. The cells were lysed 24 h after transfection. One-third of the
cell lysates was analyzed by Western blotting (WB) with anti-TAB1 and anti-Flag antibodies. The rest of the cell lysates were subjected to
immunoprecipitation (IP) with anti-Flag antibodies, and the immunoprecipitates were then analyzed by Western blotting with anti-TAB1 and
anti-Flag. (B) The same experiments as shown in panel A except TAB1 mutants with deletions after amino acids 409 (TAB1/410-504), 411
(TAB1/412-504), and 413 (TAB1/414-504) were used in the coexpression. (C) The interaction between TAB1 or TAB1 mutants and p38 was
analyzed as described in the legend to panel A. The TAB1 mutants with P412 changed to alanine (TAB1/P412A), S413 changed to alanine
(TAB1/S413A), and P412 and S413 changed to alanine (TAB1/P412A/S413A) are used. (D) The TAB1 mutants used in panels A to C are
summarized with bar graphs and their abilities to bind with p38 are indicated by  and 
. (E) 293 cells were transfected with the NF-B reporter
plasmid together with expression vectors of TAK1, TAB1, or TAB1/P412A in different combinations as indicated. Luciferase activity was measured
24 h after transfection.
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activators and substrates (43), and the ED domain (Glu160
and Asp161) was shown to confer the specificity of p38 in
binding to its substrates (44). The positions of the CD domain,
ED domain, and the hydrophobic docking groove in p38 are
shown in Fig. 3A. We examined whether CD and ED domains
of p38 are required for TAB1 binding and found that muta-
tions in the CD domain (p38CDmut) or the ED domain
(p38EDmut) did not have any effect on p38-TAB1 interac-
tion (Fig. 3B). Therefore, p38 binding to TAB1 is dissimilar
to that of p38 binding to other activators and substrates.
It is known that the R/K-X4-A-X-B peptide from MKK3
and MEF2A causes conformational changes of p38 upon
binding (5). We therefore synthesized a K-X4-A-X-B pep-
tide of TAB1 and used CD spectrum analysis to compare
conformation changes of p38 caused by R/K-X4-A-X-B
peptides from TAB1 and MKK3. As shown in Fig. 3C, TAB1
and MKK3 peptides caused changes in the CD spectra of p38
and the changes were different for each peptide. The change in
the CD absorption was large, which may come both from the
induced structure of the peptide and from rigidification of the
structure local to the TAB1-binding site (35, 40). Support for
this possibility comes from the observed rigidification (B-factor
changes) of p38 induced by peptides derived from MEF2A or
MKK3 (5). The CD spectra suggest that there are similarities
and differences between p38 interactions with peptides from
TAB1 and MKK3.
Two regions in the C-terminal domain of p38 are required
for its binding to TAB1. We then sought to determine which
residues in p38 confer the specificity of TAB1-p38 interac-
tion. p38 is a very close homologue of p38 (33, 51); the two
FIG. 2. K-X4-A-X-B motif in TAB1 is involved in TAB1-p38 interaction. (A) Sequence alignments of the K-X4-A-X-B motif near P412
in TAB1 compared to the docking sites of some known p38 activators and substrates. (B) TAB1 or TAB1 mutants with a deletion of amino acids
402 to 409 (TAB1/402-409), L407 and L409 changed to alanine (TAB1/L407A,L409A), K402 changed to alanine (TAB1/K402A), or S408 and
L409 changed to alanine (TAB1/S409A,L410A) were coexpressed with p38 in 293 cells. The interaction between p38 and TAB1 or the TAB1
mutant was analyzed as in Fig. 1A. (C) p38, p38 mutated in the docking groove (p38/I116A/Q120A), or p38 was coexpressed with TAB1. The
interaction between TAB1 and p38, the p38 mutant, or p38 was analyzed as in described in the legend to Fig. 1A.
FIG. 3. p38’s interaction with TAB1 is different from its interaction with upstream kinases and substrates. (A) Part of the p38 structure shows
the CD domain, the ED domain, and the hydrophobic docking groove bound to the MEF2A peptide (p38/pepMEF2A; Protein Data Bank [PDB]
file 1LEW). (B) p38, p38 mutated in the CD domain (p38CDmut) or ED site (p38EDmut), or p38 was coexpressed with TAB1. The
interaction between TAB1 and p38, p38 mutants, or p38 was analyzed as in Fig. 1A. (C) MKK3 peptide SKGKSKRKKDLRISCNSK or TAB1
peptide SSAQSTSKTSVTLSLVMPSQ and p38 were incubated alone or together, and the CD spectra were analyzed.
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homologues interact similarly with activating kinases and sub-
strates, but p38 cannot bind to TAB1 (12). We constructed a
series of p38/ chimeras by swapping the corresponding re-
gions of these two proteins. A coimmunoprecipitation assays
showed that the chimera p38/272-364 (in which the 88 C-
terminal amino acids of p38 were replaced by a p38 se-
quence) did not bind TAB1 (Fig. 4A). Therefore, residues at
the C terminus of p38 are required for TAB1 binding. Also,
the region spanning amino acids 176 to 272 in p38 appeared
to be required for interaction with TAB1, since p38/176-360
interacted with TAB1 while p38/272-360 did not (Fig. 4A).
Diagrams of these mutants and their ability to binding with
TAB1 are shown in Fig. 4B.
To confirm that the region from amino acids 176 to 272 in
p38 is required for p38-TAB1 interaction, we constructed
p38/176-272, a chimera of p38 and p38. p38/176-272
did not interact with TAB1 (Fig. 4C and D). We also used in
vitro pull-down to detect the interaction between TAB1 and
p38 mutants. Because recombinant TAB1 was better than
TAB1 in protein stability when expressed in Escherichia coli,
we used it in in vitro pull-down experiments. Equal amounts of
agarose beads that bound with GST-TAB1 were added into
cell lysates from the 293 cells that had been transfected with
expression plasmids of Flag-p38, Flag-p38/176-360, Flag-
p38/272-360, Flag-p38/176-272, or Flag-p38/272-364.
p38 and p38/176-360, but not the others, were pulled down
by TAB1 (Fig. 4E), which was consistent with our coimmuno-
precipitation results (Fig. 4A and C). To determine whether
the p38 mutants that cannot bind with TAB1 still interacted
with other p38-binding partners, we coexpressed green fluo-
rescent protein (GFP)-tagged MAPK-activated protein kinase
2 (MK2) with Flag-p38, Flag-p38/176-360, Flag-p38/
272-360, Flag-p38/176-272, or Flag-p38/272-364 in 293
cells. Immunoprecipitations were performed with anti-Flag an-
tibodies, and the presence of GFP-MK2 in the immunopre-
cipitates was determined by Western blot analysis using anti-
GFP antibodies. All p38 mutants interacted with MK2 (Fig.
4F). In conclusion, both the region spanning amino acids 176
to 272 and the region spanning amino acids 273 to 360 in p38
are required for p38-TAB1 interaction.
Thr218 is critical for p38-TAB1 interaction. Next, we in-
troduced point mutations to determine which amino acid(s) in
the region from Asp176 to Asn272 of p38 is required for
p38-TAB1 interaction. We mutated p38 at seven amino acid
sites between Asp176 and Asn272 that differed from the cor-
responding residues in p38. As shown in Fig. 5A, mutation of
Thr218 (p38/T218Q) abolished p38-TAB1 interaction,
while the other six point mutations had no effect. To determine
FIG. 4. The two regions in p38 that distinguish p38 from p38 in TAB1 binding. (A) p38, the p38-p38 chimeras, or p38 was coexpressed
with TAB1. The interaction between TAB1 and p38, the chimeras, or p38 was analyzed as in Fig. 1A. (B) Diagrams of the chimeras of p38
and p38 and a summary of their binding with TAB1. (C) p38, p38/176-272, or p38 was coexpressed with TAB1. The interaction between
TAB1 and p38, p38/176-272, or p38 was analyzed as described in the legend to Fig. 1A. (D) Diagram of the chimera p38/176-272. (E) A
total of 40 ml GST-TAB1 bound to glutathione-agarose was added to cell lysates from the 293 cells transfected with the expression vector of
Flag-p38, Flag-p38/176-360, Flag-p38/272-360, Flag-p38/176-272, or Flag-p38/272-364. The agarose beads were washed and subjected
to Western blot analysis with anti-Flag antibodies. The levels of these Flag-tagged proteins in the cell lysates were also determined by Western blot
analysis with anti-Flag-antibodies. (F) The GFP-MK2 expression vector was cotransfected with Flag-p38, Flag-p38/176-360, Flag-p38/272-
360, Flag-p38/176-272, or Flag-p38/272-364 expression plasmids. Immunoprecipitations were performed with anti-Flag antibodies 24 h after
transfection. Immunoprecipitates were analyzed by Western blot with anti-GFP and anti-Flag antibodies.
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whether double- or triple-amino-acid point mutations had an
additive effect on p38-TAB1 interaction, we generated three
double mutations and one triple mutation. Coimmunoprecipi-
tation assays showed that multiple amino acid mutations did
not effect p38-TAB1 interaction unless T218Q was included
in the mutation (Fig. 5B). We also performed in vitro pull-
down experiment, which confirmed that p38/T218Q did not
bind to TAB1 (Fig. 5C). Therefore, we concluded that Thr218
is a critical residue for p38-TAB1 interaction.
Ile 275 is critical for p38-TAB1 interaction. We next de-
termined which amino acids from Val273 to Ser360 in p38 are
required for p38-TAB1 interaction. The C-terminals of p38
and p38 differ after Pro351 (see Fig. S1 in the supplemental
material). We made a p38/351-364 chimera and examined
its interaction with TAB1 (Fig. 6A and B). TAB1 coimmuno-
precipitated with wild-type p38 and p38/351-364. There-
fore, these 10 C-terminal amino acids in p38 do not play a
role in the selective interaction between p38 and TAB1.
We then focused on the region from Val273 to Pro351 in
p38 and generated point mutations in p38 using the corre-
sponding amino acids from p38. Nine p38 mutants were
synthesized, and their interactions with TAB1 were examined
by coimmunoprecipitation. One of these mutants, p38/I275R,
cannot coimmunoprecipitate with TAB1. Therefore, we con-
cluded that Ile275 is another critical residue for the specific
interaction between p38 and TAB1.
Figure 7A summarizes the location of the point mutations
we made in p38. Thr218 and Ile275 are near (about 20 Å) the
hydrophobic docking groove observed crystallographically in
p38-pepMEF2A and p38-pepMKK3 complexes, in the
linker region between helices F and G, and at L14, right before
helix H. This was one locus of conformational change in p38-
pepMEF2A (Fig. 7B) and p38-pepMKK3 (5). The locations
of Thr218, Ile275, and other domains in the three-dimensional
structure of p38 and the corresponding amino acids in a
modeled structure of p38 can be found in Figure S2 in the
supplemental material.
Converting residues 218 and 275 in p38 to corresponding
amino acids of p38 leads to weak p38-TAB1 interaction. We
next evaluated whether converting key amino acids in p38 to
corresponding amino acids in p38 can result in an interaction
between p38 and TAB1. We made a series of point mutations
in p38 by converting various amino acids (Thr218, Ile275, and
a few others) to their corresponding amino acids in p38, and
we then examined their interaction with TAB1 by coimmuno-
precipitation assays. As shown in Fig. 8A, the mutant p38/
Q218T,R275I bound to TAB1, although the interaction was
relatively weak. Therefore, both Thr218 and Ile275 were re-
quired for p38-TAB1 interaction (Fig. 8A). Additionally, mu-
tations made to make p38 more like p38-enhanced TAB1
coimmunoprecipitation.
Since none of the aforementioned p38 mutants could
strongly interact with TAB1 compared with p38, it seemed
likely that more C-terminal sequences of p38 are needed for
optimal binding to TAB1. Because Thr218 is required for p38-
TAB1 interaction, we generated p38/Q218T and then made
p38/p38 chimeras (Fig. 8B). The chimera p38/Q218T/
p38272-360 coimmunoprecipitated fairly well with TAB1 (Fig.
8C). Additional mapping showed that the region from Asn272 to
Met288 in p38 was important, while the region from Leu289 to
Ser360 was not (Fig. 8C). We also studied whether the forced
p38-TAB1 interaction induces p38 phosphorylation. As shown
in Fig. 8D, p38 could be phosphorylated when it interacted with
TAB1. To determine whether these p38 mutants retain their
ability to interact with MK2, we coexpressed GFP-MK2 with
Flag-p38, Flag-p38/Q218T, Flag-p38/Q218T/R275I, or p38/
Q218,K268M,S272N,R275I and determined their interaction by
coimmunoprecipitation assays. All of these p38 mutants in-
teracted with MK2 (Fig. 8E). Our data indicated that while the
double mutant p38/Q218T/R275I binds to TAB1, optimal
interaction required the longer C-terminal sequence of p38.
Mutations in p38 that selectively abolish its interaction
with TAB1 affect some aspects of its activation. To determine
whether the p38 and p38 mutants that either lose or gain a
specific interaction with TAB1 have the same or different en-
zymatic activity, we expressed Flag-p38, Flag-p38, Flag-
FIG. 5. Thr218 in p38 is required for its interaction with TAB1.
(A) p38, p38, or p38 with point mutations at T218, T221, L234,
R237, G244, M268, or N272 (to the corresponding amino acids from
p38 at the same positions) was coexpressed with TAB1. Their inter-
action with TAB1 was analyzed as described in the legend to Fig. 1A.
(B) p38, p38, or p38 with two or three point mutations at T218,
T221, L234, or R237 (to the corresponding amino acids from p38 at
the same positions) was coexpressed with TAB1. Their interaction with
TAB1 was analyzed as described in the legend to Fig. 1A. (C) In vitro
pull-down of Flag-p38, Flag-p38, or Flag-p38/T218Q by TAB1
was performed as described in the legend to Fig. 4E.
VOL. 26, 2006 DETERMINANTS THAT CONTROL TAB1-p38 INTERACTIONS 3829
 o
n
 M
arch 20, 2017 by Xiam
en University
http://m
cb.asm
.org/
D
ow
nloaded from
 
p38/176-360, Flag-p38/176-264, Flag-p38/T218Q, Flag-
p38/I275R, or Flag-p38/Q218T,R275I in 293 cells and
stimulated the cells with hyperosmolarity (0.4 M sorbitol) to
activate these kinases. Flag-tagged p38, p38, and the various
mutants were immunoprecipitated by anti-Flag antibodies, and
the immunoprecipitates were used as enzymes in an in vitro
kinase assay with GST-ATF2 (1 to 109) as a substrate. p38,
p38, and the mutants phosphorylated ATF2 in vitro and their
activities were comparable (Fig. 9A). We also tested other p38
substrates, including tristetraprolin and myelin basic protein,
and did not find any difference in substrate specificity among
p38 and its mutants (Fig. 9B). This suggests that the muta-
tions affecting the interaction between TAB1 and either p38
or p38 do not affect the kinase activity of p38 or p38.
To determine if the p38 mutants that cannot bind to TAB1
can still be activated by its upstream kinases, we coexpressed
p38, p38/T218Q, or p38/I275R expression vectors with
control (empty), TAB1, or dominant active MKK6 [MKK6(E)]
FIG. 6. Ile275 in p38 is required for its interaction with TAB1. (A) p38, p38, or p38/351-364 was coexpressed with TAB1. Their
interaction with TAB1 was analyzed as described in the legend to Fig. 1A. (B) Diagram of p38/351-364. (C) p38, p38, or p38 with single
point mutations at V273, I275, V282, K287, E286, K295, E301, Q325, or V349 (to the corresponding amino acids from p38 at the same positions)
was coexpressed with TAB1. Their interaction with TAB1 was analyzed as described in the legend to Fig. 1A.
FIG. 7. (A) A summary of point mutations on the three-dimensional structure of p38 complexed with pepMEF2A (PDB file 1LEW).
Mutations affecting TAB1 binding are shown as large green spheres. Mutations that do not affect TAB1 binding are shown as small spheres.
Placement of the B2 residue in pepMEF2A is labeled. B3 could bind in the active site. Note that the activation loop is missing in 1LEW.
(B) The location of residues Thr218 and Ile275 in relation to the p38 docking groove and the MEF2A docking-site peptide (PDB file 1LEW;
green) overlaid with uncomplexed p38 (1P38; gray). Note that the peptide-induced conformational changes in p38 helices D and E and the linker
between them.
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mutant expression vectors. p38 phosphorylation was deter-
mined by Western blot analysis with anti-phospho-p38 anti-
bodies. Coexpression of TAB1 resulted in phosphorylation of
p38 but not p38/T218Q or p38/I275R (Fig. 9C). Coexpres-
sion of MKK6(E) led to phosphorylation of p38 and the two
mutants (Fig. 9C). To further confirm the activation of p38/
T218Q and p38/I275R by MKK6, we used an ATF2-depen-
dent reporter. As shown in Fig. 9D, p38, p38/T218Q, and
p38/I275R all enhanced MKK6(E)-induced ATF2 reporter
gene expression. Therefore, T218 and I275 mutations in p38
do not influence MKK6-mediated p38 activation.
Basal activity of p38 can be detected, but a relatively large
amount of protein is needed. We overexpressed Flag-p38,
Flag-p38/T218Q, and Flag-p38/I275R in 293 cells and iso-
lated them by immunoprecipitation with anti-Flag antibodies.
The basal activities of p38 and its mutants were analyzed by
Western blot analysis using anti-phospho-p38 antibodies, and
the amounts of these proteins were analyzed by Western blot-
ting with anti-Flag antibodies. p38/T218Q had a much lower
level of basal activity than p38 (Fig. 9E). The basal level
phosphorylation of p38/I275R was between those of p38
and p38/T218Q. To determine whether abolishing p38-
TAB1 interaction affects p38 activation by extracellular stim-
uli, we transiently expressed Flag-p38 and Flag-p38/T218Q
in 293 cells and stimulated the cells with peroxynitrite, sorbitol,
or tumor necrosis factor. Flag-p38 and Flag-p38/T218Q
were immunoprecipitated, and their protein levels and enzy-
matic activities in the immunoprecipitates were determined by
Western blot analysis with anti-Flag and anti-phospho-p38 an-
tibodies, respectively. p38 was activated by all three stimuli,
while p38/T218Q was activated by hyperosmolarity (sorbitol)
but not others. Therefore, interaction with TAB1 plays some
role in stimulus-induced p38 activation.
DISCUSSION
The interaction between TAB1 and p38 is unique among
MAP kinases in that p38 is the only MAP kinase known to
autophosphorylate naturally (29). There are no known homo-
logues of TAB1 acting on different MAP kinases. In this study,
we made several observations that bring us closer to under-
standing how TAB1 induces p38 autophosphorylation. First,
we found that Pro412 of TAB1 is essential for TAB1 binding to
p38. This residue is in the B3 position of a putative D-
domain. Although it is atypical, we were able to confirm that
the sequence K402TSVTLSLVMP412 in TAB1 is a docking site
for p38. Furthermore, we found that p38/I116A and p38/
Q120A, which are mutated in the previously identified docking
FIG. 8. The interaction between p38 mutants and TAB1. (A) p38, p38, or p38 with point mutations at Q218; Q218 and A221; Q218 and
I273; Q218, R243 and E237; Q218 and R275; or Q218, K268, S272, and R275 (to the corresponding amino acids from p38 at the same positions)
was coexpressed with TAB1. The interaction with TAB1 was analyzed as described in the legend to Fig. 1A. (B) Diagrams of p38 mutants with
Q218 mutated to threonine and C-terminal fragments replaced by sequences from p38. (C) p38, p38, or the p38 mutants described in the
legend to panel B were coexpressed with TAB1. Their interaction with TAB1 was analyzed as described in the legend to Fig. 1A. (D) p38, p38,
or p38 with point mutations at Q218, Q218, and R275 or at Q218, K268, S272, and R275 (to the corresponding amino acids from p38 at the
same positions) was coexpressed with TAB1. The phosphorylation of p38, p38, or the p38mutants was determined by Western blotting analysis
with anti-phospho-p38 antibodies. (E) GFP-MK2 was coexpressed with Flag-p38, Flag-p38/Q218T, Flag-p38/Q218T,R275I, or Flag-p38/
Q218T,K268M,S272N,R275I. Immunoprecipitations were performed with anti-Flag antibodies 24 h after transfection. Immunoprecipitates were
analyzed by Western blotting with anti-GFP and anti-Flag antibodies.
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groove for the AXB motif, are unable to interact with TAB1.
We also found that the CD and ED domains do not contribute
to this interaction. In the structure of p38/pepMEF2A (5), a
proline residue is present in B2 but is not tightly bound to
the surface of p38. Model building suggests that Pro412 in
TAB1 could make closer contacts near the active site of p38.
Lastly, through a series of mutagenic analyses, we found that
Thr218 and Ile275 of p38 are essential for TAB1 binding.
These residues are apparently specific for TAB1 interaction,
since they have yet to appear in screens of p38 interaction
sites in other studies, and we show that their mutations have no
effect on p38 binding with MK2. In addition, the p38 family
members that cannot interact with TAB1 share the same up-
stream kinases (MKK3 and MKK6), and downstream sub-
strates have amino acids replacements in one or both of these
positions. Therefore, both common and unique sites in p38
contribute to its specific interactions with TAB1.
Thr218 and Ile275 are near the hydrophobic docking groove
(Fig. 7), but model building suggests that a continuous
polypeptide in TAB1 would not be able to bind to both the
docking groove and the cleft flanked by Thr218 and Ile275.
Therefore, it seems likely that some other part of TAB1 may
interact with this region. Since the C-terminal portion of TAB1
(Arg333 to Pro504) is sufficient to bind p38 but insufficient to
cause p38 phosphorylation (data not shown) and since the
C-terminal up to Ser413 is not required for TAB1 to interact
with p38 (Fig. 1), the sites that are involved in the interaction
with the cleft flanked by Thr218 and Ile275 may be outside the
region from Arg333 to Ser413. Thr218 and Ile275 are adjacent
to helix D, which undergoes conformational changes upon
p38 binding to D-domain peptides derived from MEF2A and
MKK3 (Fig. 7). The fact that TAB1 binds in the docking
groove also suggests that similar conformational changes are
occurring in the p38-TAB1 complex. While the MAP kinases
JNK1 (20) and ERK2 (H. Zhou and E. J. Goldsmith, unpub-
lished data) do not change shape in this locus in the presence
of D-domain docking sites, both p38 and JNK1 are known to
undergo long-range conformational changes that affect the
conformation and order of the activation loop. Therefore, a
plausible model is that TAB1 binding utilizes and enhances the
conformational change induced by the docking site and
Pro412, forming a unique conformation of p38 that is capable
of autophosphorylation.
Sequence alignments of mammalian MAPKs reveals that
several, including p38	 and p38, have a threonine at the
position corresponding to Thr218 in p38, but none contains
FIG. 9. Activity and activation of p38 mutants that cannot interact with TAB1. (A) Expression vector of Flag-p38, Flag-p38, Flag-p38/
176-360, Flag-p38/176-264, Flag-p38/T218Q, Flag-p38/I275R, or Flag-p38/Q218T,R275I was transfected into in 293 cells. At 24 h after
transfection, the cells were treated with 0.4 M sorbitol for 30 min. Flag-tagged proteins were immunoprecipitated with anti-Flag antibodies. An
in vitro kinase assay was performed using the immunoprecipitates as kinases and GST-ATF2 as a substrate. The levels of immunoprecipitated
Flag-proteins were determined by Western blot analysis with anti-Flag antibodies. (B) Flag-p38, Flag-p38/T218Q, and Flag-p38/I275R were
prepared by immunoprecipitations as described in the legend to panel A and used as kinases. GST-ATF2, tristetraprolin, or myelin basic protein
was used as a substrate in the kinase assays. (C) Flag-p38, Flag-p38/T218Q, or Flag-p38/I275R was coexpressed with control (empty vector),
TAB1, or MKK6(E) in 293 cells as indicated. Total cell lysates were analyzed 24 h after transfection by Western blotting with anti-phospho-p38
and anti-Flag antibodies. (D) Expression vectors of a luciferase reporter gene under the control of 5 GAL4-binding site (5xGal), GAL4-binding
domain fused with ATF2 activation domain (Gal-ATF2), MKK6(E), Flag-p38, Flag-p38/T218Q, or Flag-p38/I275R were transfected into 293
cells in different combinations as indicated. Luciferase activity was measured 24 h later. (E) 293 cells were transfected with empty (control),
Flag-p38, Flag-p38/T218Q, or Flag-p38/I275R expression vectors. Flag-tagged proteins were immunoprecipitated with anti-Flag antibodies
48 h after transfection. The immunoprecipitates were analyzed by Western blotting using anti-phospho-p38 and anti-Flag antibodies. (F) Flag-p38
or Flag-p38/T218Q was expressed in 293 cells. At 48 h after transfection, the cells were treated with peroxynitrite (500 M), tumor necrosis factor
(100 ng/ml), or sorbitol (0.4 M) for 5, 30, and 30 min, respectively. Flag-p38 or Flag-p38/T218Q was immunoprecipitated with anti-Flag
antibodies. The phosphorylation and the levels of Flag-p38 or Flag-p38/T218Q were analyzed by Western blotting with anti-phospho-p38 and
anti-Flag antibodies.
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an isoleucine corresponding to Ile275. This sequence informa-
tion is consistent with our conclusion that both Thr218 and
Ile275 are required for selective interaction between p38 and
TAB1. The requirement of the common docking groove in
p38 for its interaction with TAB1 is consistent with our data
that an R/K-X4-A-X-B motif in TAB1 is involved in the
interaction. We found that Pro412 at the 3 position to B in
TAB1 is required for p38 binding (Fig. 1). Proline residues
can be found adjacent to the C terminus of the R/K-X4-A-
X-B motif of several p38-interacting proteins (Fig. 2A), al-
though none is exactly at the 3 position of B. To date, there
is no report indicating that proline residues adjacent to the C
terminus of the R/K-X4-A-X-B motif of MAPK-interacting
proteins are required for their binding to MAPK. Perhaps
Pro412 in TAB1 sits in a relatively hydrophobic pocket of p38
and this hydrophobic interaction is essential for TAB1-p38
interaction. The involvement of the common docking groove in
p38-TAB1 interactions may also contribute to the phosphor-
ylation of TAB1 by p38 (6). However, p38 phosphorylation
site mutations in TAB1 to either alanine or aspartic acid res-
idues did not affect p38-TAB1 interactions by coimmunopre-
cipitation assays (data not shown), suggesting that p38-TAB1
interactions and TAB1 phosphorylation are independent
events. Furthermore, TAB1 can be efficiently phosphorylated
by other MAPKs, and no interaction between these MAPKs
and TAB1 can be detected by coimmunoprecipitation assays
(6, 12).
Although autophosphorylation is a common mechanism for
the activation of other kinases, such as receptor tyrosine ki-
nases (14, 19, 28, 46), its role in MAPK activation was not
realized until the discovery of a number of gain-of-function
mutants in ERK and p38 by genetic screens and in vitro
mutagenesis (3, 4, 10). Although the mutation sites of these
gain-of-function mutants affect different regions of the kinases,
all of the mutations seem to enhance autophosphorylation and
lead to constitutive activation of MAPKs. Very recently, Sal-
vador et al. showed that phosphorylation on Tyr323 in p38 by
tyrosine kinase Zap70 also led to p38 auto-activation (36). It
is highly possible that a common conformational change in
MAPKs underlies autophosphorylation initiated through dif-
ferent mechanisms. Crystallographic studies of docking-site
interactions in MAPKs have already suggested that MAPKs
can adopt different conformations within the activation loop in
response to binding by other proteins (5), and the action of
TAB1 binding may be related to the conformational changes
induced by docking-site interactions.
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